{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:20Z","timestamp":1790349020015,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with type 2 diabetes face a high residual risk of atherosclerotic cardiovascular disease (ASCVD) despite advances in therapy. Once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide, offers the potential to simultaneously address glycemic control, weight, and multiple cardiometabolic risk factors with a single weekly injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a PRISMA-compliant systematic review and random-effects meta-analysis of randomized trials from the COMBINE program. Data from COMBINE 1 (active comparator: once-weekly insulin icodec) and COMBINE 3 (active comparator: basal-bolus insulin therapy) (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091,970) were pooled comparing IcoSema with insulin-based intensification strategies in patients inadequately controlled on basal insulin. COMBINE 2 was excluded because its semaglutide monotherapy comparator addresses a fundamentally different clinical question (escalation from GLP-1 RA monotherapy). The primary focus was on changes in body weight, Systolic blood pressure and HbA1c; key secondary outcomes included changes in lipid profile relevant to ASCVD risk. Certainty of evidence was assessed using GRADE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IcoSema showed no statistically significant difference in HbA1c reduction compared with control (pooled MD -0.37%, 95% CI -0.95 to 0.21;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.21; I\u00b2=98%) but shows highly significant body weight reduction (pooled MD -6.10\u00a0kg, 95% CI -7.21 to -5.00;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001). It significantly lowered systolic blood pressure (MD -2.45 mmHg, 95% CI -3.52 to -1.38;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001), total cholesterol (ETR 0.97, 95% CI 0.95\u20130.98;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001), LDL-C (ETR 0.94, 95% CI 0.90\u20130.98;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005), triglycerides (ETR 0.94, 95% CI 0.91\u20130.97;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0006), and VLDL-C (ETR 0.94). An exploratory, hypothetical ASCVD risk modeling analysis based on these surrogate-marker changes is presented in the Supplementary Appendix and is intended as an illustration only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once-weekly IcoSema delivers meaningful improvements in weight, blood pressure, and atherogenic lipids, all key modifiable drivers of ASCVD in adults with type 2 diabetes. These surrogate benefits, combined with reduced injection burden and low risk of hypoglycemia, suggest potential for enhanced ASCVD prevention and improved long-term adherence. Results should be interpreted as hypothesis-generating only because only two trials met the inclusion criteria. Dedicated cardiovascular outcome trials are essential to validate these surrogate-marker benefits and to confirm whether they translate into a reduction in cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-026-00333-0","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:08:37Z","timestamp":1788300517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2290-605X","authenticated-orcid":false,"given":"Adir","family":"Alper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ashraf","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksheeth","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Faillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes. Lancet. 2022;400:1803\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5.","journal-title":"Lancet"},{"key":"333_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06633-x","author":"VC Bertuol","year":"2025","unstructured":"Bertuol VC, Iorra F, Vieceli T, et al. Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis. Diabetologia. 2025. https:\/\/doi.org\/10.1007\/s00125-025-06633-x.","journal-title":"Diabetologia"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"e34718","DOI":"10.1097\/MD.0000000000034718","volume":"102","author":"P Zhang","year":"2023","unstructured":"Zhang P, Bao Y, Chen M, et al. Changes of health-related quality of life after initiating basal insulin treatment among people with type 2 diabetes. Medicine. 2023;102:e34718. https:\/\/doi.org\/10.1097\/MD.0000000000034718.","journal-title":"Medicine"},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"573235","DOI":"10.3389\/fendo.2021.573235","volume":"12","author":"AM Boels","year":"2021","unstructured":"Boels AM, Rutten G, Cleveringa F, et al. Insulin Therapy in Type 2 Diabetes Is Associated With Barriers to Activity and Worse Health Status: A Cross-Sectional Study in Primary Care. Front Endocrinol. 2021;12:573235. https:\/\/doi.org\/10.3389\/fendo.2021.573235.","journal-title":"Front Endocrinol"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/dc16-1957","volume":"40","author":"MI Maiorino","year":"2017","unstructured":"Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017;40:614\u201324. https:\/\/doi.org\/10.2337\/dc16-1957.","journal-title":"Diabetes Care"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/dom.16593","volume":"27","author":"JP Frias","year":"2025","unstructured":"Frias JP. What is the \u2018real-world\u2019 experience with fixed\u2010ratio combination therapy (insulin\u2009+\u2009GLP \u20101 receptor agonist) in routine clinical practice? Take\u2010home messages for clinicians regarding key outcomes. Diabetes Obes Metabolism. 2025;27:26\u201341. https:\/\/doi.org\/10.1111\/dom.16593.","journal-title":"Diabetes Obes Metabolism"},{"key":"333_CR8","doi-asserted-by":"publisher","unstructured":"Weeda ER, Muraoka AK, Brock MD, Cannon JM. Medication adherence to injectable glucagon-like peptide\u20101 (GLP\u20101) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta\u2010analysis. Int J Clin Pract. 2021;75. https:\/\/doi.org\/10.1111\/ijcp.14060.","DOI":"10.1111\/ijcp.14060"},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-8587(22)00388-6","volume":"11","author":"J Frias","year":"2023","unstructured":"Frias J, Chien J, Zhang Q, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol. 2023;11:158\u201368. https:\/\/doi.org\/10.1016\/S2213-8587(22)00388-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diabres.2019.05.025","volume":"153","author":"H Ito","year":"2019","unstructured":"Ito H, Ando S, Tsugami E, et al. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:41\u20138. https:\/\/doi.org\/10.1016\/j.diabres.2019.05.025.","journal-title":"Diabetes Res Clin Pract"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.2023.11313","volume":"330","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Asong M, Desouza C, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA. 2023;330:228. https:\/\/doi.org\/10.1001\/jama.2023.11313.","journal-title":"JAMA"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023;389:297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208.","journal-title":"N Engl J Med"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407:892\u2013908. https:\/\/doi.org\/10.1016\/S0140-6736(25)02105-1.","journal-title":"Lancet"},{"key":"333_CR14","doi-asserted-by":"publisher","unstructured":"Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the american heart association. Circulation. 2022;145. https:\/\/doi.org\/10.1161\/CIR.0000000000001040.","DOI":"10.1161\/CIR.0000000000001040"},{"key":"333_CR15","doi-asserted-by":"publisher","unstructured":"Lee MMY, Sattar N, Pop-Busui R et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025. https:\/\/doi.org\/10.2337\/dc25-0241.","DOI":"10.2337\/dc25-0241"},{"key":"333_CR16","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","volume":"41","author":"F Marsico","year":"2020","unstructured":"Marsico F, Paolillo S, Gargiulo P, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41:3346\u201358. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa082.","journal-title":"Eur Heart J"},{"key":"333_CR17","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L, et al. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1781\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071689.","journal-title":"Circulation"},{"key":"333_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","volume":"68","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Benamar M, Chen L, et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 2025;68:739\u201351. https:\/\/doi.org\/10.1007\/s00125-024-06348-5.","journal-title":"Diabetologia"},{"key":"333_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S2213-8587(25)00052-X","volume":"13","author":"LK Billings","year":"2025","unstructured":"Billings LK, Andreozzi F, Frederiksen M, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13:556\u201367. https:\/\/doi.org\/10.1016\/S2213-8587(25)00052-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-8587(25)00096-8","volume":"13","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Giorgino F, Kim SG, et al. Once\u2013weekly IcoSema versus once\u2013weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open\u2013label, multicentre, treat\u2013to\u2013target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13:568\u201379. https:\/\/doi.org\/10.1016\/S2213-8587(25)00096-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"333_CR21","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"333_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range, and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"333_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"333_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jacc.2023.07.018","volume":"82","author":"JR Medina-Inojosa","year":"2023","unstructured":"Medina-Inojosa JR, Somers VK, Garcia M, et al. Performance of the ACC\/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice. J Am Coll Cardiol. 2023;82:1499\u2013508. https:\/\/doi.org\/10.1016\/j.jacc.2023.07.018.","journal-title":"J Am Coll Cardiol"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamainternmed.2018.2875","volume":"178","author":"S Mora","year":"2018","unstructured":"Mora S, Wenger NK, Cook NR, et al. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women\u2019s Health Initiative. JAMA Intern Med. 2018;178:1231\u201340. https:\/\/doi.org\/10.1001\/jamainternmed.2018.2875.","journal-title":"JAMA Intern Med"},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.aed.2025.07.012","volume":"12","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan ABM, Chatterjee S, Nagendra L, et al. Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. AACE Endocrinol Diabetes. 2025;12:153\u201361. https:\/\/doi.org\/10.1016\/j.aed.2025.07.012.","journal-title":"AACE Endocrinol Diabetes"},{"key":"333_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of Insulin Injection Omission. Diabetes Care. 2010;33:240\u20135. https:\/\/doi.org\/10.2337\/dc09-1348.","journal-title":"Diabetes Care"},{"key":"333_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1463-1326.2012.01636.x","volume":"14","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P\u2010M. Factors associated with injection omission\/non\u2010adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metabolism. 2012;14:1081\u20137. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01636.x.","journal-title":"Diabetes Obes Metabolism"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00333-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:08:38Z","timestamp":1788300518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00333-0","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"59"}}